Dataset Information

New medical therapies on the horizon: oral octreotide.

ABSTRACT: Somatostatin analog treatment is first line medical treatment in patients with acromegaly. This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide. With the innovative transient permeability enhancer, a technology enabling the absorption of drug molecules via transient opening of the tight junctions of the gut epithelium, it is possible to achieve therapeutic octreotide levels after oral ingestion. The present review summarized the preclinical work and the recently reported phase I and III study on oral octreotide capsules in patients with acromegaly. Maintenance of control in 155 participating patients was achieved in 65% at the end of core period. Once controlled on oral octreotide, the response was maintained to the end of the extension phase in 85%. Side effects were comparable to currently available preparations. There was a profound suppression of growth hormone levels, and significant symptom reduction. Currently available parental somatostatin analogs are generally well tolerated and are able to achieve longstanding biochemical control in patients with somatostatin sensitive tumors. Potential advantages of an oral alternative is the lack injection-related side effects, but there will be an ongoing need for a very strict compliance with the 2 daily dose regimen and fasting around drug administrations. A second phase III study is currently being conducted. The potential place in the treatment of acromegaly is discussed.

SUBMITTER: Biermasz NR

PROVIDER: S-EPMC5334421 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

New medical therapies on the horizon: oral octreotide.

Biermasz Nienke R NR

Pituitary 20170201 1

Somatostatin analog treatment is first line medical treatment in patients with acromegaly. This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide. With the innovative transient permeability enhancer, a technology enabling the absorption of drug molecules via transient opening of the tight junctions of the gut epithelium, it is possible to achieve therapeutic octreotide levels after oral ingestion. The present review summarized the preclinical work a ...[more]

PMID: 28091879

Similar Datasets

Project description:Genodermatoses are rare inherited skin diseases that frequently affect other organs. They often have marked effects on wellbeing and may cause early death. Progress in molecular genetics and translational research has unravelled many underlying pathological mechanisms, and in several disorders with high unmet need, has opened the way for the introduction of innovative treatments. One approach is to intervene where cell-signaling pathways are dysregulated, in the case of overactive pathways by the use of selective inhibitors, or when the activity of an essential factor is decreased by augmenting a molecular component to correct disequilibrium in the pathway. Where inflammatory reactions have been induced by a genetically altered protein, another possible approach is to suppress the inflammation directly. Depending on the nature of the genodermatosis, the implicated protein or even on the particular mutation, to correct the consequences or the genetic defect, may require a highly personalised stratagem. Repurposed drugs, can be used to bring about a "read through" strategy especially where the genetic defect induces premature termination codons. Sometimes the defective protein can be replaced by a normal functioning one. Cell therapies with allogeneic normal keratinocytes or fibroblasts may restore the integrity of diseased skin and allogeneic bone marrow or mesenchymal cells may additionally rescue other affected organs. Genetic engineering is expanding rapidly. The insertion of a normal functioning gene into cells of the recipient is since long explored. More recently, genome editing, allows reframing, insertion or deletion of exons or disruption of aberrantly functioning genes. There are now several examples where these stratagems are being explored in the (pre)clinical phase of therapeutic trial programmes. Another stratagem, designed to reduce the severity of a given disease involves the use of RNAi to attenuate expression of a harmful protein by decreasing abundance of the cognate transcript. Most of these strategies are short-lasting and will thus require intermittent life-long administration. In contrast, insertion of healthy copies of the relevant gene or editing the disease locus in the genome to correct harmful mutations in stem cells is more likely to induce a permanent cure. Here we discuss the potential advantages and drawbacks of applying these technologies in patients with these genetic conditions. Given the severity of many genodermatoses, prevention of transmission to future generations remains an important goal including offering reproductive choices, such as preimplantation genetic testing, which can allow selection of an unaffected embryo for transfer to the uterus.

Project description:We assessed the clinical features and treatment outcome in immunocompetent patients of primary central nervous system lymphoma (PCNSL) by retrospective chart review from 2005–12. Overall survival was analyzed by Kaplan-Meier method. 17 patients met the study criterion (male: female = 11:6). Median age at presentation was 47 years (range 15–74 years). Presenting features included motor impairment in 8(47.06%), raised intracranial tension in 6(35.29%) and seizures in 3(17.65%) patients. Contrast enhanced MRI of brain revealed periventricular lesion, with homogenous contrast enhancement and perilesional edema. Lesions were unifocal in 8(47.06%) and multifocal in 9(52.94%) patients. Stereotactic biopsy and decompression of tumor were performed in 2(11.76%) and 7(41.18%) patients respectively whereas the remaining 8(47.06%) patients were treated on basis of radiology. Histopathology showed diffuse large B cell lymphoma (CD20 + ve) in all 9 patients. Systemic lymphoma workup was negative in all patients. Systemic chemotherapy (median 6 cycles) was given in 14(82.35%) patients. The most common regimen incorporated high dose methotrexate (3gm/m2 IV D1 q3wk) with leucovorin rescue in 12(70.59%) patients- single agent in 10 and in combination in 2 patients. Whole brain radiation (WBRT-median dose 45Gy/25fractions/5weeks) was given in 12(70.59%) patients. After a median follow-up of 21 months (mean 26.24 months), 9(52.94%) patients are in complete response, 2(11.76%) patients are alive with evidence of disease and 6(35.29%) patients expired due to disease progression. The median overall survival was noted to be 34 months (actuarial rate of overall survival at 2 and 3 years- 63.3% and 43.4% respectively). On univariate analysis (Log rank test), KPS (<70 versus ?70) was a significant predictor of overall survival (p = 0.01) whereas age, sex, extent of surgery, treatment modality and choice of chemotherapy had no significant impact upon survival. Stereotactic biopsy followed by high dose single agent methotrexate with WBRT is a reasonable treatment strategy for PCNSL in a developing nation.

Dataset Information

New medical therapies on the horizon: oral octreotide.

Publications

New medical therapies on the horizon: oral octreotide.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets